Spots Global Cancer Trial Database for cancer of unknown primary site
Every month we try and update this database with for cancer of unknown primary site cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | NCT04969835 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... Head and Neck C... Cancer of Unkno... Ovarian Cancer Breast Cancer Soft Tissue Sar... Bladder Cancer Oesophageal Can... Prostate Cancer Biliary Tract C... | AVA6000 | 18 Years - | Avacta Life Sciences Ltd | |
| Trial of Pembrolizumab in Cancer of Unknown Primary | NCT03752333 | Cancer of Unkno... | Pembrolizumab | 18 Years - | Imperial College London | |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | NCT04459273 | Bladder Carcino... Cervical Carcin... Cholangiocarcin... Hematopoietic a... Hepatocellular ... Malignant Adren... Malignant Brain... Malignant Pleur... Malignant Skin ... Malignant Solid... Malignant Testi... Malignant Thymu... Neuroendocrine ... Thyroid Gland C... Urothelial Carc... Cancer of Unkno... | Computed Tomogr... Gallium Ga 68 F... Positron Emissi... 18F-FDG | 18 Years - | Jonsson Comprehensive Cancer Center | |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | NCT03053466 | Solid Tumor Microsatellite ... Mismatch Repair... Cancer of Unkno... | APL-501 | 18 Years - | Apollomics (Australia) Pty. Ltd. | |
| Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary | NCT05841966 | Cancer of Unkno... Unknown Primary... Unknown Primary... | Transoral Ultra... | 18 Years - | Rigshospitalet, Denmark | |
| Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary | NCT03278600 | Cancer of Unkno... | tissue-of-origi... | 18 Years - 75 Years | Fudan University | |
| Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary | NCT05841966 | Cancer of Unkno... Unknown Primary... Unknown Primary... | Transoral Ultra... | 18 Years - | Rigshospitalet, Denmark | |
| Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China | NCT04952103 | Cancer of Unkno... | no intervention | - | Fudan University | |
| Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers | NCT04750109 | Cancer of Unkno... | 16 Years - | The Christie NHS Foundation Trust | ||
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study | NCT04504604 | Rare Cancers Cholangiocarcin... Cancer of Unkno... | FoundationOne C... | 18 Years - | TargetCancer Foundation | |
| APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | NCT03053466 | Solid Tumor Microsatellite ... Mismatch Repair... Cancer of Unkno... | APL-501 | 18 Years - | Apollomics (Australia) Pty. Ltd. | |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine | NCT01845337 | Gastrointestina... Cancer of Unkno... Pancreatic Canc... Bile Duct Neopl... | Teysuno Capecitabine | 18 Years - 100 Years | University of Edinburgh | |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study | NCT04504604 | Rare Cancers Cholangiocarcin... Cancer of Unkno... | FoundationOne C... | 18 Years - | TargetCancer Foundation | |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study | NCT04504604 | Rare Cancers Cholangiocarcin... Cancer of Unkno... | FoundationOne C... | 18 Years - | TargetCancer Foundation | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China | NCT04952103 | Cancer of Unkno... | no intervention | - | Fudan University | |
| Sintilimab in Cancer of Unknown Primary | NCT05024968 | Cancer of Unkno... | Sintilimab | 18 Years - | M.D. Anderson Cancer Center | |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study | NCT04504604 | Rare Cancers Cholangiocarcin... Cancer of Unkno... | FoundationOne C... | 18 Years - | TargetCancer Foundation | |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine | NCT01845337 | Gastrointestina... Cancer of Unkno... Pancreatic Canc... Bile Duct Neopl... | Teysuno Capecitabine | 18 Years - 100 Years | University of Edinburgh | |
| Trial of Pembrolizumab in Cancer of Unknown Primary | NCT03752333 | Cancer of Unkno... | Pembrolizumab | 18 Years - | Imperial College London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
